Table 1 Patient characteristics at baseline
Patients included (n = 3810) | Patients with a 2 year FU* (n = 3058) | |
|---|---|---|
Age (years) | 65.9 (57.6–72.9) | 66.1 (57.7–72.9) |
Female gender (%) | 46.7 | 46.7 |
Body weight (kg) | 88 (78–100) | 88 (78–100) |
Diabetes duration (years) | 5.5 (2.9–9.4) | 5.6 (2.9–9.4) |
Lipid values | ||
LDL-C (mg/dL) | 120 (98–145) | 119 (96–145) |
HDL-C (mg/dL) | 47 (40–57) | 47 (40–56) |
TG (mg/dL) | 176 (127–242) | 175 (127–241) |
TC (mg/dL) | 204 (175-232) | 211 (181-235) |
Blood pressure (mmHg) | 137/80 | 137/80 |
Blood glucose | ||
HbA1c (%) | 7.4 (6.8–8.3) | 7.4 (6.8–8.2) |
FPG (mg/dL) | 142 (119–171) | 141 (119–169) |
PPG (mg/dL) | 185 (155–221) | 183 (155–220) |
Hypoglycaemia requiring assistance (%) | 1.2 | 1.4 |
Concomitant disease (%) | ||
Prior MI (%) | 6.0 | 5.8 |
Prior stroke/TIA (%) | 4.6 | 4.8 |
HF (%) | 9.9 | 9.9 |
PAD (%) | 6.0 | 6.2 |
Prior amputation (%) | 0.9 | 0.9 |
Any neuropathy (%) | 15.9 | 14.5 |
Any retinopathy (%) | 4.2 | 4.2 |
Vascular disease (%)** | 24.0 | 24.3 |
Cardiovascular pharmacotherapy | ||
ACEi | 50.0 | 50.5 |
ARB | 21.8 | 21.9 |
Betablocker | 46.6 | 46.5 |
CCB | 24.9 | 25.4 |
Diuretic | 41.2 | 42.0 |
ASA | 33.6 | 33.8 |
Statin | 42.2 | 42.6 |
Antidiabetic therapy post baseline | ||
Metformin (%) | 84.5 | 84.5 |
Sulfonylureas (%) | 26.2 | 27.2 |
Glucosidase inhibitors (%) | 2.3 | 2.6 |
Glinides (%) | 6.0 | 5.3 |
DPP-4 inhibitors (%) | 38.8 | 39.3 |
Glitazones (%) | 10.3 | 10.1 |
GLP-1 analogues (%) | 9.2 | 9.7 |
Insulin (%) | 17.3 | 17.6 |